CAMP4 Therapeutics Form 4 / Andrew J. Schwab ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Schwab Andrew J.

(Last)

(First)

(Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2024		C⁽¹⁾		1,337,592	A	⁽¹⁾	1,337,592	I	See Footnote⁽²⁾
Common Stock	10/15/2024		C⁽³⁾		378,463	A	⁽³⁾	1,716,055	I	See Footnote⁽²⁾
Common Stock	10/15/2024		C⁽³⁾		302,770	A	⁽³⁾	302,770	I	See Footnote⁽⁴⁾
Common Stock	10/15/2024		P		909,090	A	$11	2,625,145	I	See Footnote⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Prime Preferred Stock	⁽¹⁾	10/15/2024		C			15,002,166	⁽¹⁾	⁽¹⁾	Common Stock	1,337,592	⁽¹⁾	0	I	See Footnote⁽²⁾
Series B Preferred Stock	⁽³⁾	10/15/2024		C			4,244,770	⁽³⁾	⁽³⁾	Common Stock	378,463	⁽³⁾	0	I	See Footnote⁽²⁾
Series B Preferred Stock	⁽³⁾	10/15/2024		C			3,395,816	⁽³⁾	⁽³⁾	Common Stock	302,770	⁽³⁾	0	I	See Footnote⁽⁴⁾

Explanation of Responses:

1. On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series A Convertible Preferred Stock had no expiration date.

2. The reported securities are held directly by 5AM Ventures VI, L.P. ("5AM Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of 5AM Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to share voting and investment power over the shares held by 5AM Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

3. On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.

4. The reported securities are held by 5AM Opportunities II, L.P. ("5AM Opportunities"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of 5AM Opportunities. The Reporting Person is a managing member of Opportunities II GP and may be deemed to share voting and investment power over the shares held by 5AM Opportunities. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

	By: /s/ Thomas Danielski, Attorney-in-Fact	10/15/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CAMP4 Therapeutics Form 4Camp4 Therapeutics / Andrew J. Schwab ownership change